London
· Delayed Price · Currency is GBP · Price in GBXCeladon Pharmaceuticals Statistics
Total Valuation
Celadon Pharmaceuticals has a market cap or net worth of GBP 24.41 million. The enterprise value is 27.89 million.
| Market Cap | 24.41M |
| Enterprise Value | 27.89M |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Celadon Pharmaceuticals has 65.98 million shares outstanding. The number of shares has increased by 8.03% in one year.
| Shares Outstanding | 65.98M |
| Shares Change (YoY) | +8.03% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 55.80% |
| Owned by Institutions (%) | 19.64% |
| Float | 27.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 305.53 |
| PB Ratio | 7.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.91 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.42 |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 148.29.
| Current Ratio | 2.62 |
| Quick Ratio | 2.20 |
| Debt / Equity | 148.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.75 |
| Interest Coverage | -10.68 |
Financial Efficiency
Return on equity (ROE) is -142.14% and return on invested capital (ROIC) is -39.71%.
| Return on Equity (ROE) | -142.14% |
| Return on Assets (ROA) | -34.58% |
| Return on Capital (ROIC) | -39.71% |
| Revenue Per Employee | 2,778 |
| Profits Per Employee | -264,444 |
| Employee Count | 27 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 1.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.57% |
| 50-Day Moving Average | 50.10 |
| 200-Day Moving Average | 85.67 |
| Relative Strength Index (RSI) | 44.67 |
| Average Volume (20 Days) | 168,644 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celadon Pharmaceuticals had revenue of GBP 75,000 and -7.14 million in losses. Loss per share was -0.12.
| Revenue | 75,000 |
| Gross Profit | 1,000 |
| Operating Income | -6.22M |
| Pretax Income | -7.52M |
| Net Income | -7.14M |
| EBITDA | -5.85M |
| EBIT | -6.22M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 1.26 million in cash and 4.72 million in debt, giving a net cash position of -3.46 million or -0.05 per share.
| Cash & Cash Equivalents | 1.26M |
| Total Debt | 4.72M |
| Net Cash | -3.46M |
| Net Cash Per Share | -0.05 |
| Equity (Book Value) | 3.18M |
| Book Value Per Share | 0.05 |
| Working Capital | 1.55M |
Cash Flow
In the last 12 months, operating cash flow was -5.97 million and capital expenditures -341,000, giving a free cash flow of -6.31 million.
| Operating Cash Flow | -5.97M |
| Capital Expenditures | -341,000 |
| Free Cash Flow | -6.31M |
| FCF Per Share | -0.10 |
Margins
| Gross Margin | 1.33% |
| Operating Margin | -8,288.00% |
| Pretax Margin | -10,030.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -8,417.33% |
Dividends & Yields
Celadon Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.03% |
| Shareholder Yield | -8.03% |
| Earnings Yield | -31.18% |
| FCF Yield | -25.86% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |